AbbVie Inc. (ABBV) announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for its JAK inhibitor, Rinvoq (upadacitinib), for a new indication.The company is seeking approval for once-daily Rinvoq (15 mg) for treating adult patients with giant cell arteritis (GCA), an autoimmune disease-causing inflammation of the large arteries.The regulatory filings for GCA were based on data from the phase III SELECT-GCA study, which evaluated the safety ...

Anna Moneymaker/Getty Images News Listen below or on the go on Apple Podcasts and Spotify. Former president says he is OK after rally shooting. (0:16) Netflix highlights earnings week. (1:39) Dividend calendar. (2:15) This is an abridged transcript: Donald Trump’s campaign says he is “fine” after what law enforcement officials are treating as an assassination attempt during a rally in Butler, Pennsylvania. The AP reports that officials said the man who opened fire was a 20-year-old from Pennsylvania. ...

What's better than a dividend? A dividend that's growing.Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields.Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold. Here's why they picked AbbVie (ABBV 0.22%), Amgen (AMGN 1.77%), and Gilead Sciences (GILD -0.01%).Keeping a 52-year streak goingKeith Speights (A ...

The prices of these reliable dividend payers haven't kept pace with the frothy stock market.The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains.Shares of Johnson & Johnson (JNJ 0.12%), Agree Realty (ADC 0.63%), and AbbVie (ABBV 0.22%) offer enticing dividend yields at recent prices -- and they could raise their pay ...

文章核心观点 - 公司已向美国FDA和欧洲EMA提交了upadacitinib(RINVOQ®)用于治疗巨细胞动脉炎(GCA)的新适应症申请[2] - 该申请是基于SELECT-GCA III期临床试验结果,upadacitinib联合26周糖皮质激素减量方案在第12周至第52周期间达到了持续缓解的主要终点[5][6] - upadacitinib在GCA患者中的安全性概况与已批准适应症一致[1] 根据相关目录分别进行总结 GCA疾病概况 - GCA是一种中大型动脉的自身免疫性疾病,可引起头痛、颌痛和视力改变,包括突然和永久性视力丧失[3][7] - 该病主要发生在50岁以上的白人女性,尤其是70-80岁之间,但男性更容易出现眼部并发症[7] 临床试验情况 - SELECT-GCA III期临床试验旨在评估upadacitinib在GCA患者中的安全性和有效性[6] - 该试验包括两个阶段,第一阶段比较了upadacitinib联合26周糖皮质激素减量方案与安慰剂联合52周糖皮质激素减量方案在持续缓解率方面的疗效[6] - 第二阶段正在评估对于第一阶段达到持续缓解的患者,继续使用upadacitinib与停药在维持缓解方面的疗效和安全性[6] 药物信息 - upadacitinib(RINVOQ®)是公司自主研发的JAK抑制剂,正在多种免疫介导性炎症性疾病中进行III期临床试验,包括GCA、强直性脊柱炎、克罗恩病等[8] - 该药物对JAK-1的抑制作用优于JAK-2、JAK-3和TYK-2,但具体抑制哪些JAK酶与疗效和安全性的关系尚不清楚[8] - 目前upadacitinib在GCA适应症尚未获批,其安全性和有效性也未经监管部门评估[8]

AbbVie (ABBV) stock has gained 24.0% compared with an increase of 34.3% for the industry in the past year, as seen in the chart below.Image Source: Zacks Investment ResearchAbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023. Before it lost patent exclusivity, Humira accounted for a significant percentage of AbbVie’s sales, around 37% in 2022. Amgen (AMGN) was the first company to launch its Humira biosimilar. Thereafter, several other biosimilar ver ...

文章核心观点 - 这篇文章介绍了一些高收益的股息贵族公司,这些公司连续25年或更长时间提高了股息,被认为是优质和稳定的公司[1] - 尽管这些公司的股价也会下跌,但它们通常能够更快地反弹回来[2] - 这些公司的股息收益率是标准普尔500指数的近3倍,是很好的投资选择[5] 公司和行业总结 房地产投资信托(REIT)公司Realty Income (O) - Realty Income是一家月度派息的REIT公司,连续29年提高派息,是股息贵族中最出色的之一[6][7][9] - 该公司主要投资于零售物业,主要租户包括美元店、药店和便利店等[7][8] - 该公司的股息收益率为5.9%,其调整后的经营活动现金流(AFFO)可以支撑其股息[9] 包装公司Amcor (AMCR) - Amcor是全球最大的食品和饮料包装公司,受到通胀和高利率的影响,股价在过去一年中基本持平[11][12] - 但该公司作为行业龙头,可以通过规模优势来降低成本,并通过提高价格或转向利润更高的细分市场来提高利润[13] - 尽管增长不会太快,但该公司的股息收益率为5.1%,为投资者提供了稳定的收益[14] 制药公司AbbVie (ABBV) - AbbVie是一家制药公司,通过从母公司Abbott Labs分拆继承了其股息支付历史,过去10年股息复合年增长率达14%[15][16] - 尽管其主要药物Humira面临专利到期的挑战,但该公司仍有其他多个十亿美元级别的药品,并通过收购其他公司来拓展产品线[16][17][18] - 该公司的股息收益率为3.7%,股息支付能力很强[15] 消费品公司Kimberly-Clark (KMB) - Kimberly-Clark是一家消费品领导者,拥有多个知名品牌,在通胀压力下也能保持业绩[19][20] - 虽然消费者在通胀时会选择更便宜的产品,但当通胀缓解时他们通常会回到熟悉的品牌[21] - 该公司的股息增长率过去10年只有3.8%,但股息支付率仍然很安全[23] 消费健康公司Kenvue (KVUE) - Kenvue是强生公司(Johnson & Johnson)分拆出来的全球最大的消费健康公司,拥有知名品牌如泰诺、创可贴等[24][25] - 作为前母公司强生的继承者,Kenvue有望继续保持稳定的股息支付[25] - 该公司的股息收益率为4.3%[25] 可口可乐公司(KO) - 可口可乐是一家饮料巨头,虽然碳酸饮料消费呈下降趋势,但公司已转型为多元化的饮料公司[26][27][28] - 公司拥有强大的分销网络,可以快速推广新产品[28] - 公司有57年的连续增加股息的历史,过去10年股息复合增长率为4.8%,最近一次增幅为5.4%[29] 石油公司雪佛龙(CVX) - 雪佛龙是全球第二大综合性石油天然气公司,在疫情期间没有暂停或减少股息[30][31] - 即使油价下跌至每桶50美元,公司也能保持盈利并支付股息[31] - 公司未来5年内现金流有望超过一倍,为股息支付提供保障[31] - 公司当前股息收益率为4.1%[31]

NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second- quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and so ...

One of the most important sectors in any country’s economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results. These companies have to move past the clinical trials and then prove that their drug or treatment is effective and safe. There are times when many of these candidates hit a dead wall, and the investment and research both go in vain. But if the company proves its worth, the rewards will be significant. This is why it takes a ...

Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years. Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%. Dividend stocks are more resilient, so this outperformance is even greater during market volatility. This is great, since the markets are sti ...